Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (April 2022)

46 slides from Windtree Therapeutics's investor presentation, Apr 20, 2022

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics eR Company Overview XK) WINDTREE THERAPEUTICS

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company

  3. Slide 3: Windtree Therapeutics Highlights

    Windtree Therapeutics Highlights Biopharmaceutical company with advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ: WINT) CA Clinical programs focused on significant markets with high unmet needs and with supportive regulatory paths: * One clinical program rece

  4. Slide 4: Windtree Therapeutics Pipeline

    Windtree Therapeutics Pipeline Lead Products Phase of Development| Next Milestone FDA Fast Track |staroxime Phase 2b * Study start up ongoing for second Phase Designation (Acute Heart Failure) 2b clinical trial in ~300 patients targeted to start once cl operations are fully funded Potential for Ista

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones Early Cardiogenic TO _ meet reo st Shock (ECS) Study ‘Announced Registration Study Istaroxime i ECS Extension Stud genic Shock EEE 4 Ais monts Istaroxime Acute Heart Failure Study ng nto na, Heart Failure (transition to Phase 3)** oil See Oral SERCA2a A

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure and Early Cardiogenic Shock.

  7. Slide 7: Heart Failure — Large, Growing Market But Underserved

    Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing > 6MU.S., 20M+ worldwide patients Vv #1 cause of U.S. hospitalization in patients > 65 years old; * >1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) Vv In-patie

  8. Slide 8: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need "= Clinical objectives for AHF = Current approaches to acutely improve patient management include: cardiac function are associated with * Relieve pulmonary congestion unwanted effects: and general edema (e.g., “dry * Heart rhythm disturbances out

  9. Slide 9: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Inhibition of the sodium. 2 Stimulation of SERCA2a activity ‘ . enhances calcium reuptake resulting in potassium pumpandeffectson [StQrOXIME improvement of

  10. Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary

    Istaroxime AHF Phase 2a & 2b Studies —- Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients mB Oh © n=120 Dosing= 6 hour Phase one patients 0.5, 1, 1.5 ye/ts/min Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 0.5, 1.0 ue/ig/min Infusion (dyspnea plus need for

  11. Slide 11: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio) and Stroke Volume Istaroxime 0.5 yg/kg/min vs. placebo Istaroxime 1.0 g/kg/min vs. placebo 20 20 19 19 oo co 10 9% ge Bao 40 y eae cae Efe’ 5 50 so Tafusion period * infusion ped = * pvalues $0,038 Secine Shows hows Bows Beene Shaws 2éhous

  12. Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 yg/kg/min vs. placebo Istaroxime 1.0 ug/kg/min vs. placebo 2 ————— 9 i Systolic = & Blood 3 Pressure = 2 (sp) 6. «| hake t 5 TP yvalue=0.011, * p-values s0:006 fa ee a oe woth gre att =2= Pocebo-Co

  13. Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins Istaroxime 0.5 yg/kg/min vs. placebo Istaroxime 1.0 g/kg/min vs. placebo a ° £ si—aa 6 S$ __infustonperid infusion period Bo Heart . E23 Rate 3 i it : o-¢ ba + pvalve= ods : Mes dorset Sas as sae oS SS SS SE Ee Oe 9 Pracebo-Conort 1 —gentste

  14. Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias Clinically Significant Arrhythmias OK — 105% 105% s05% 250% 200% 200% 200% 200% 150% 125% hoox " 200% a 2 - | ox rhe ay Lee Bune i wPlocebo-Cohert 1 misaroxime0S uKe/min smPlocebo-Coher 2 tonanesouete nin _

  15. Slide 15: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally* Enrich therapeutic impact

  16. Slide 16: Istaroxime Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development

  17. Slide 17: Cardiogenic Shock

    Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf

  18. Slide 18: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need > No satisfactory pharmacological intervention to reverse the conditions * Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction an

  19. Slide 19: Early Cardiogenic Shock Treatment: Accelerated Pathway

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway FDA Regulatory Commentary with Break-Through Therapy Designation Potential Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drugs to treat h

  20. Slide 20: Changes in SBP — Phase 2a and 2b Dose Groups

    Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion 10.0 8.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study 0.5 ug/kg/min 1.0 pig/kg/min 1.5 yg/kg/min Study/Dose SBP Mean Change o & Mean SBP at Baseline ~112 mmHg ™6Hours ™24 H

  21. Slide 21: SEISMiC Early Cardiogenic Shock Study

    SEISMiC Early Cardiogenic Shock Study Early cardiogenic shock study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure &% 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF in the EU and US Study drug was infused for 24 hours in

  22. Slide 22: SEISMiC Study Results

    line Study Results SEISMIC was a Positive Study in SCAI Stage B Early Cardiogenic Shock Patients = The study met its primary endpoint in SBP profile over six hours, with the istaroxime treated group performing significantly better compared to the control group. = Further details of study results are

  23. Slide 23: SEISMiC Extension Study

    SEISMIC Extension Study (amendment to the ECS study) Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology

  24. Slide 24: SEISMiC Trial — Relevance to the Acute Heart Failure Program

    SEISMIC Trial — Relevance to the Acute Heart Failure (AHF) Program = The early cardiogenic shock trial results are consistent with Windtree’s Phase 2 AHF studies and complementary to further advancement in AHF. = While SEISMIC was an early cardiogenic shock study, because the patients studied had ve

  25. Slide 25: Next Steps for Early Cardiogenic Shock and the Year Ahead

    Next Steps for Early Cardiogenic Shock and the Year Ahead for Windtree = Plan to present more data from SEISMIC at the European Society of Cardiology (ESC) Heart Failure Meeting in May of 2022 and publish the trial results = Start the Extension Study to further optimize the dosing regimen for the ea

  26. Slide 26: Next Generation, Oral SERCA2a Activators

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & i.v. therapies for chronic heart = “Next generation istarox

  27. Slide 27: Lyo Lucinactant

    Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in Og COVID-19 Patients ® rh

  28. Slide 28: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function

    COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function i a Uses angiotensin- ‘ACE2is surface molecule on converting enzyme 2 alveolar Type 2 lung cells ~ (ACE2) for entry into host the source of surfactant cells RS. Surfactant is necessary for lungs to stay inflated

  29. Slide 29: Phase 2 Study of Lucinactant for Treatment of COVID-19 ARDS

    Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 ARDS Objective: Demonstrate safe and tolerable surfactant administration and changes in physiological parameters in COVID-19-associated lung injury and ARDS a * Open-label, single arm study in 20 patients from sites in US and La

  30. Slide 30: AEROSURF

    AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS)

  31. Slide 31: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli

  32. Slide 32: AEROSURF — Potential to Impact the Clinical Course of RDS

    AEROSURF® — Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Long-Term Outcomes Reduced Rates and Severity of BPD 2 WINDTREE ae Noninvasive RDS treatment Improved Respiratory Study results show Parameters evidence of potential impact on clinical cours

  33. Slide 33: AEROSURF Program Evolution and Strategy

    AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach “1 Execute small (n=~80 - 90) Bridging Study to transition to EOP2/Phase 3: + Demonstrate that new ADS works and supplement Phase 2 data + Optimize dosing with more drug and shorter repeat intervals Y Transition

  34. Slide 34: Financial Summary & Capitalization as of December 31, 2021

    Financial Summary & Capitalization as of December 31, 2021 = Cash & Equivalents of ~$22.3 million Common Equivalents Rosle as of March 30, 2022 Common Stock 28,469,274 Options (WAEP $8.02) 4,183,033 Restricted Stock Units 549,000 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 49,830,109

  35. Slide 35: Strategy for Value Generation

    Strategy for Value Generation se we WINDTREE THERAPEUTICS” G Communicate Our Milestones: Share the results from our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts - set new milestones for the future G Transactions: * Secure focused BD transactio

  36. Slide 36: Windtree Therapeutics

    Windtree Therapeutics “Striving to Deliver Hope for a Lifetime!” S@ winotREe ae

  37. Slide 37: Appendix

    Appendix SB winvtRee BE merrcunce

  38. Slide 38: Acute Heart Failure

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need = Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

  39. Slide 39: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo- E controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% * SBP 90-150 mmHg

  40. Slide 40: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events Istaroxime 0.5 Istaroxime 1.0 me/Ke/min me/Ke/min (n=41) {n=40) All adverse events 23 (59.0%) 31 (75.6%) 33 (82.5%) ‘Adverse events leading to discontinuation Pooled placebo {n=39) 1(2.6%) . 4 (10.0%) Serious adverse events 2(5.1%) 2 (4.9%) 6 (15.0%) Cardiac death

  41. Slide 41: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza = Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur

  42. Slide 42: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID-19 Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicability of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic Demonstrated Utility of

  43. Slide 43: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include 2 a =~ invasive and noninvasive method

  44. Slide 44: Windtree Technology Platform — AEROSURF

    Windtree Technology Platform — AEROSURF® Proprietary Synthetic KLa Surfactant Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLa surfactant (intratracheal instillate) ally ionsermeciiea Miaantectane for RDS approved by the FDA Lyophilize

  45. Slide 45: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® Surfactant Therapy Reversing surfactant deficiency has a profound positive impact on respiration ‘Surfactant therapy delivers near-immediate clinical improvement BPD Infection, ventilator-induced pneumonia RISKS cord damage, asthma, lung damage nCPAP. Respirator

  46. Slide 46: Business Development Focus

    Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia Mid-term Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Out

Windtree Therapeutics — Investor Presentation (April 2022) on 6ix